Answers are grounded in this paper and cite their sources.
This cost-effectiveness analysis demonstrated that switching from PCV15 2 + 1 to PCV20 3 + 1 in the Dutch paediatric NIP would reduce both the clinical burden and projected costs of pneumococcal disease over 10 years.
No takes yet. Share an insight, caveat, or question.
Çakar et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: